Role of microRNAs in HTLV-1 infection

Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 394

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NGCMED10_032

تاریخ نمایه سازی: 16 تیر 1397

Abstract:

The human T cell leukemia virus-1 (HTLV-1) is a retrovirus that causes adultT cell leukemia (ATL) and the neurodegenerative disease, HTLV-1-associatedmyelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP is a diseasewith important biological similarities to multiple sclerosis.MicroRNAs (miRNAs) are a new class of a small group of non-coding RNAmolecules that regulate gene expression at the post-transcriptional level bydegrading or blocking translation of messenger RNA (mRNA). SincemicroRNAs affect cellular proliferation, differentiation, modulationinflammatory and ultimately, can play a part in neurologic disease such asHAM/TSP. We investigated their roles in HTLV-1 pathogenesis.Several articles reported that miRNAs expression in HTLV-1 infected directlyinduced by Tax through activation of NF-κB signaling. Also, some of themiRNAs lead to up-regulated by Tax via promoter activation mediated by NF-κB. Numerous study demonstrated an associated between HTLV-1 infect andmodulation of human miRNA expression. Despite the efforts to characterizemiRNA expression profiles, only a few studies functionally analyzed themiRNAs in HAM/TSP and ATL patient.In the present review study, we discuss the recognized functions andcharacteristics of microRNAs and their role in the HTLV-1 infect. MicroRNAsare essential for modulating the expression of TAX in HAM/TSP and ATL.Suggested, they are great promise as a new non-invasive biomarker forclinical diagnosis that can be targeted by novel classes of drugs. The completecomprehension of the miRNAs function will thus provide insights into theseprocesses and might diagnostic and therapeutic advances in HAM/TSPtreatment and significantly reduce the risk of patient relapse.

Authors

Zohreh Vahidi

HTLV-۱ Foundation, Mashhad University of Medical Sciences, Mashhad, Iran

Houshang Rafatpanah

Inflammation and Inflammatory Diseases Research Centre, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Reza Boostani

Department of Neurology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences,Mashhad, Iran

Fariba Zemorshidi

Department of Neurology, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences,Mashhad, Iran